PORT WASHINGTON, NY – July 18, 2018 – Pall Corporation, a global leader in filtration, separation and purification, is pleased to announce the extension of a consumables distribution agreement with KANEKA Corporation. In addition to flagship KANEKA KanCapA Protein A chromatography sorbents, the Pall Biotech business unit now features the company’s next generation KANEKA KanCapA 3G sorbent for the primary capture of monoclonal antibodies (mAbs) from clarified cell culture. The sorbents are available in off-the-shelf bulk format for use with large columns, such as Resolute® AutoPak columns, and a range of pre-packed columns.

“Increasing demand for more targeted and personalized medicines is driving growth and development in the mAb manufacturing market. In combination with our industry-leading portfolio of downstream process equipment, KANEKA KanCapA 3G sorbent offers a complete solution to customers looking to make these products,” said Mario Philips, Vice President and General Manager at Pall Biotech. “Through the collaboration with the KANEKA team we are able to ensure consistency, quality and reliability with an industry-leading sorbent that enables customers to continuously improve their bioprocesses.”

The full KANEKA KanCapA line of products is based on a robust matrix that enables the high productivity affinity capture of mAbs and related biomolecules using a proprietary alkali stable rPrA ligand. Designed with a combination of proprietary recombinant ligand and a highly cross-linked cellulose base matrix, the new KANEKA KanCapA 3G sorbent exhibits enhanced binding capacity, an excellent elution profile, and advanced impurity removal properties when compared with other market sorbents. Furthermore, KANEKA KanCapA products are manufactured in a state-of-the-art facility in Japan to meet and exceed regulatory standards, deliver exceptional results, and guarantee supply chain security.

The distribution agreement between Pall and KANEKA enables market reach expansion for KANEKA products which, ultimately, helps to improve global health.


About Kaneka Corporation

KANEKA Corporation is an innovation-oriented chemical company. Traditionally the company has been active in polymers, fermentation, biotechnology and electronics, as well as other fields. Business activities now span a broad spectrum of markets ranging from plastics, EPS resins, chemicals and foodstuffs to pharmaceuticals, medical devices, electrical and electronic materials and synthetic fibers. The life science related activities are currently one of the strategically

important domains for Kaneka. To learn more, please visit: http://www.kaneka.co.jp/en/

Kaneka Contact
For more information on the full line of KANEKA KanCapA sorbents, please visit: http://www.bioseparation.kaneka.com/ or email bioproducts@kaneka.co.jp


About Pall Corporation

Pall Corporation is a filtration, separation and purification leader, providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide.

For more information visit www.pall.com

Or follow us on social media: YouTube -   LinkedIn - Twitter - Facebook

Pall Corporate Media Contact

Pall Corporation

Mariann Kourafas

Director of Communications


Pall Media Contact

White Matter Communications

Beth Willers



More Biotech Press Releases
Read all the latest news and developments from Pall and keep in touch with industry trends and opinion.
July 2019
July 16, 2019: Servier chooses Pall as exclusive technology and services provider for planned Bio-S biomanufacturing facility in France
April 2019
April 29, 2019: Freeline's (AAV) manufacturing platform and Pall’s iCELLis bioreactor system combine to achieve commercial-scale and high quality production of AAV gene therapy vectors
March 2019
March 19, 2019: New lab will serve as a dedicated platform where the industry can access shared resources including equipment, expertise and project work to find innovative solutions to manufacturing needs for biologic medicines, such as cell-based immunotherapies
March 13, 2019: Pall Biotech to distribute ARTeSYN’s standard hardware and liner components for fluid flow control. Customers to benefit from the flexibility, agility and reliability required for their bioprocessing journey, with accelerated implementation of robust and standardized single-use fluid management and control
March 11, 2019: Pall Biotech to integrate and distribute Broadley-James’ advanced single-use probe and flow cell pH sensors; sensor will be integrated into Pall Biotech’s single-use technologies
December 2018
December 18, 2018: New centre to give Pall customers options ranging from batch to single use and continuous bioprocessing solutions, and to provide technology solutions that meet current needs, while offering some of the most progressive technological solutions for the future
November 2018
November 26, 2018: Cobra and Pall to make commercialisation of gene therapies safer, faster, and cheaper than ever before, help increase patient access to gene therapy and further establish best practices in manufacturing
October 2018
October 2, 2018: New centre will work to enhance drug production and empower the future workforce, reinforcing Pall's commitment to continuously improve bioprocesses through strategic partnerships
September 2018
September 24, 2018: New collaboration to see G-CON PODs customized with Pall technologies, addressing customer demand for higher efficiencies, while enjoying more flexibility through scale-out and localization of manufacturing
September 11, 2018: Pall and Aetos partner to combine bioreactors, mixing and storage, and downstream technologies with cell lines and manufacturing processes for expedited biosimilars development